The bill would direct the National Institute of Standards and Technology Director to competitively award a grant or other transaction agreement to an eligible non-Federal entity to establish and operate a National Biopharmaceutical Manufacturing Center of Excellence. The center would advance biopharmaceutical manufacturing, support manufacturing practices and workforce training, and conduct collaborative research; the bill would require reports to Congress and authorize $120,000,000 for fiscal year 2026.

FactVote-generated overview; it is not an official CRS summary.